Sarepta Therapeutics (SRPT) is back in focus after investors reacted to expectations for late 2026 clinical data in facioscapulohumeral muscular dystrophy and myotonic dystrophy, alongside developments in its Duchenne therapy Elevidys and a competitor setback.
Sarepta Therapeutics' recent 1 day share price return of 10.95% and 30 day share price return of 39.92% suggest momentum has picked up as traders react to the Elevidys update and reduced competition. However, the 3 year total shareholder return, which is down 82.16%, underlines how sentiment has shifted over a longer horizon.
Look beyond Sarepta Therapeutics and compare this move with a hand picked 20 high quality undiscovered gems that are also reacting to research milestones and changing competitive pressure.
The share price has sprinted ahead while fair value estimates sit in a much tighter band. With Sarepta Therapeutics only slightly below the average analyst target and a wide implied intrinsic discount, where does a reasonable valuation range fall now?
Most Popular Narrative: 30% Undervalued
The most followed narrative pegs Sarepta Therapeutics at a fair value of $21.65, almost exactly in line with the last close at $21.59, yet still classed as undervalued on that framework.
The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.
Want to understand why this framework still calls Sarepta Therapeutics undervalued? The narrative leans on shrinking losses, a profitability turn and a premium future earnings multiple tied to specific 2029 targets.
Result: Fair Value of $21.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sarepta Therapeutics still faces meaningful risks, including ongoing safety scrutiny around Elevidys and high research spending that could keep profitability under pressure.
Find out about the key risks to this Sarepta Therapeutics narrative.
Another View: Multiples Paint A Different Picture For Sarepta Therapeutics
Our DCF work describes Sarepta Therapeutics as deeply undervalued, with the model pointing to a future cash flow value of $612.22 per share against a market price of $21.59. That is a very large gap. It raises a fair question about how much model risk an investor may be willing to accept.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Given the mix of optimism around Sarepta Therapeutics and clear areas of concern, it makes sense to check the details yourself and move quickly to shape your own view by weighing the 1 key reward and 1 important warning sign.
Looking for more investment ideas beyond Sarepta Therapeutics?
If Sarepta Therapeutics has sharpened your focus on opportunities, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh ideas that match your style.
- Spot potential mispricing early and review a focused set of 46 high quality undervalued stocks that may suit a value driven approach.
- Prioritise resilience and scan a curated 76 resilient stocks with low risk scores that score well on Simply Wall Street's risk filters.
- Strengthen your watchlist by checking a list of solid balance sheet and fundamentals (50 results) that can support growth plans through tougher periods.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com